Crinetics Pharmaceuticals, INC Form 4 insider transactions

Crinetics Pharmaceuticals' Chief Operating Officer, Jeff E. Knight, sold 501 shares of common stock at $56.52 per share under a pre-arranged 10b5-1 trading plan.

Dana Pizzuti, Chief Medical and Development Officer of Crinetics Pharmaceuticals, executed stock options and sold shares on October 3, 2024, according to a recent SEC filing.

Crinetics Pharmaceuticals CFO Marc Wilson exercised stock options and sold 25,000 shares of common stock on September 26, 2024, according to a Form 4 filing.

Stephen F. Betz, Chief Scientific Officer of Crinetics Pharmaceuticals, sold 1,035 shares of common stock at an average price of $51.50 per share under a pre-arranged Rule 10b5-1 trading plan.

Stephen F. Betz, Chief Scientific Officer of Crinetics Pharmaceuticals, sold 3,000 shares of common stock on August 26, 2024, at a price of $53.19 per share.

Stephen F. Betz, Chief Scientific Officer of Crinetics Pharmaceuticals, sold 3,000 shares of common stock on August 12, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Stephen F. Betz, Chief Scientific Officer of Crinetics Pharmaceuticals, sold 3,000 shares of common stock on July 25, 2024, under a pre-arranged Rule 10b5-1 trading plan.

CFO Marc Wilson exercised stock options and sold shares of Crinetics Pharmaceuticals on July 25, 2024, according to a Form 4 filing with the SEC.

Jeff E. Knight, Chief Operating Officer of Crinetics Pharmaceuticals, reports the exercise of stock options and sale of common stock on July 15, 2024, according to a Form 4 filing.

Crinetics Pharmaceuticals CFO Marc Wilson exercised stock options and sold 25,000 shares of common stock on July 15, 2024, according to a Form 4 filing.

Stephen F. Betz, Chief Scientific Officer of Crinetics Pharmaceuticals, sold 3,000 shares of common stock at an average price of $48.55 per share under a pre-arranged Rule 10b5-1 trading plan.

Chief Commercial Officer James Hassard exercised stock options and sold shares of Crinetics Pharmaceuticals on July 5, 2024, according to a Form 4 filing.

Dana Pizzuti, Chief Medical and Development Officer of Crinetics Pharmaceuticals, exercised stock options and sold shares on July 3, 2024, according to a recent SEC filing.

CFO Marc Wilson exercised stock options and sold shares of Crinetics Pharmaceuticals on June 28, 2024, according to a recent SEC filing.

Jeff E. Knight, Chief Operating Officer of Crinetics Pharmaceuticals, sold 956 shares of common stock on June 26, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Stephen F. Betz, Chief Scientific Officer of Crinetics Pharmaceuticals, sold 3,000 shares of common stock on June 25, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Dana Pizzuti, Chief Medical and Development Officer at Crinetics Pharmaceuticals, reports the exercise of stock options and subsequent sale of shares on June 24, 2024.

Crinetics Pharmaceuticals' Chief Commercial Officer, James Hassard, exercised stock options and sold 15,000 shares of common stock on June 21, 2024, according to a Form 4 filing.

Stephen F. Betz, Chief Scientific Officer of Crinetics Pharmaceuticals, sold 3,000 shares of common stock at $43.86 per share on June 10, 2024, under a pre-arranged 10b5-1 trading plan.

Director Caren Deardorf reports acquisition of restricted stock units and stock options in Crinetics Pharmaceuticals, Inc.

Director Vivaldi Coelho Rogerio reported the acquisition of restricted stock units and stock options in Crinetics Pharmaceuticals.

Director Stephanie Okey received stock options and restricted stock units from Crinetics Pharmaceuticals on June 7, 2024.

Director Nichols Weston reports acquiring 3,400 shares of Crinetics Pharmaceuticals common stock and disposing of 9,400 shares, along with receiving options to purchase 12,500 shares.

Director Matthew K Fust reports acquisition of restricted stock units and stock options in Crinetics Pharmaceuticals.

Director Camille L. Bedrosian reports acquisition of 3,400 shares of common stock and 12,500 stock options in Crinetics Pharmaceuticals.

Director Wendell Wierenga reports acquisition of 3,400 shares of common stock and 12,500 stock options in Crinetics Pharmaceuticals.

Stephen F. Betz, Chief Scientific Officer of Crinetics Pharmaceuticals, sold 3,000 shares of common stock on May 28, 2024, at an average price of $47.49 per share.

Stephen F. Betz, Chief Scientific Officer of Crinetics Pharmaceuticals, sold 3,000 shares of common stock on May 10, 2024, at a price of $49.43 per share.

Crinetics Pharmaceuticals' CEO Richard Struthers exercised stock options and sold shares on May 8, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Richard Scott Struthers, CEO of Crinetics Pharmaceuticals, reported a gift of 350 shares of common stock in a recent SEC filing.